| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 108 | 2025 | 188 | 32.180 |
Why?
|
| Fatty Liver | 28 | 2025 | 106 | 8.620 |
Why?
|
| Liver Cirrhosis | 46 | 2025 | 272 | 7.450 |
Why?
|
| Liver Transplantation | 28 | 2025 | 1193 | 4.880 |
Why?
|
| Liver | 31 | 2025 | 1205 | 2.520 |
Why?
|
| Metabolic Diseases | 6 | 2025 | 57 | 2.400 |
Why?
|
| Fibroblast Growth Factors | 6 | 2025 | 84 | 2.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2025 | 1229 | 2.010 |
Why?
|
| Humans | 147 | 2025 | 93130 | 1.780 |
Why?
|
| Disease Progression | 13 | 2023 | 1528 | 1.480 |
Why?
|
| Chenodeoxycholic Acid | 6 | 2023 | 9 | 1.370 |
Why?
|
| End Stage Liver Disease | 5 | 2025 | 73 | 1.330 |
Why?
|
| Risk Factors | 30 | 2025 | 5900 | 1.090 |
Why?
|
| Obesity | 18 | 2025 | 1014 | 1.020 |
Why?
|
| Cardiovascular Diseases | 5 | 2025 | 752 | 0.980 |
Why?
|
| Metabolic Syndrome | 4 | 2023 | 122 | 0.940 |
Why?
|
| Consensus Development Conferences as Topic | 5 | 2023 | 50 | 0.930 |
Why?
|
| Gastroenterologists | 2 | 2023 | 31 | 0.900 |
Why?
|
| Global Health | 5 | 2023 | 207 | 0.900 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2025 | 416 | 0.890 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1054 | 0.890 |
Why?
|
| Delphi Technique | 6 | 2025 | 135 | 0.860 |
Why?
|
| Life Style | 4 | 2019 | 183 | 0.850 |
Why?
|
| Bariatric Surgery | 4 | 2017 | 208 | 0.840 |
Why?
|
| Female | 54 | 2025 | 48540 | 0.830 |
Why?
|
| Double-Blind Method | 18 | 2025 | 1727 | 0.830 |
Why?
|
| Diet | 5 | 2019 | 461 | 0.810 |
Why?
|
| Liver Diseases | 4 | 2024 | 243 | 0.810 |
Why?
|
| Sarcopenia | 2 | 2024 | 20 | 0.790 |
Why?
|
| Gastrointestinal Agents | 2 | 2023 | 181 | 0.790 |
Why?
|
| Biopsy | 15 | 2025 | 1172 | 0.790 |
Why?
|
| Patient Selection | 2 | 2025 | 688 | 0.780 |
Why?
|
| Liver Neoplasms | 8 | 2025 | 773 | 0.770 |
Why?
|
| Hypoglycemic Agents | 5 | 2024 | 378 | 0.760 |
Why?
|
| Prevalence | 12 | 2020 | 1318 | 0.750 |
Why?
|
| Disease Management | 2 | 2024 | 357 | 0.740 |
Why?
|
| United States | 22 | 2024 | 7581 | 0.740 |
Why?
|
| Micronutrients | 2 | 2013 | 18 | 0.740 |
Why?
|
| Male | 50 | 2025 | 44353 | 0.730 |
Why?
|
| Physicians, Primary Care | 1 | 2023 | 106 | 0.730 |
Why?
|
| Weight Loss | 4 | 2022 | 234 | 0.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 393 | 0.720 |
Why?
|
| Biomarkers | 12 | 2025 | 1905 | 0.700 |
Why?
|
| Treatment Outcome | 28 | 2025 | 9070 | 0.700 |
Why?
|
| Terminology as Topic | 4 | 2023 | 219 | 0.700 |
Why?
|
| Primary Health Care | 3 | 2023 | 369 | 0.690 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1098 | 0.670 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1908 | 0.660 |
Why?
|
| Postoperative Complications | 4 | 2023 | 2552 | 0.660 |
Why?
|
| Risk Assessment | 14 | 2024 | 2434 | 0.650 |
Why?
|
| Steroids | 1 | 2021 | 166 | 0.650 |
Why?
|
| Adult | 37 | 2025 | 27849 | 0.630 |
Why?
|
| Middle Aged | 39 | 2025 | 27535 | 0.630 |
Why?
|
| Insulin Resistance | 8 | 2025 | 379 | 0.620 |
Why?
|
| Exercise | 5 | 2018 | 353 | 0.620 |
Why?
|
| Anticholesteremic Agents | 2 | 2018 | 154 | 0.610 |
Why?
|
| Hepatomegaly | 3 | 2023 | 11 | 0.600 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 1849 | 0.590 |
Why?
|
| Rosuvastatin Calcium | 1 | 2018 | 31 | 0.570 |
Why?
|
| Thiazolidinediones | 2 | 2016 | 76 | 0.570 |
Why?
|
| Choline Deficiency | 3 | 2011 | 4 | 0.570 |
Why?
|
| Methionine | 3 | 2011 | 64 | 0.550 |
Why?
|
| Epidemics | 4 | 2021 | 41 | 0.540 |
Why?
|
| Severity of Illness Index | 12 | 2025 | 1910 | 0.540 |
Why?
|
| Ethanol | 3 | 2024 | 273 | 0.500 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 107 | 0.490 |
Why?
|
| Alcohol Drinking | 7 | 2025 | 283 | 0.490 |
Why?
|
| Diabetes Complications | 2 | 2015 | 167 | 0.490 |
Why?
|
| Comorbidity | 7 | 2023 | 1003 | 0.480 |
Why?
|
| Alanine Transaminase | 6 | 2019 | 72 | 0.470 |
Why?
|
| Waiting Lists | 4 | 2025 | 211 | 0.470 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 95 | 0.470 |
Why?
|
| Pentoxifylline | 2 | 2016 | 7 | 0.470 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2025 | 59 | 0.470 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2021 | 123 | 0.470 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 31 | 0.460 |
Why?
|
| Fatty Liver, Alcoholic | 2 | 2025 | 8 | 0.460 |
Why?
|
| Fibrosis | 6 | 2024 | 228 | 0.450 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 97 | 0.430 |
Why?
|
| Coronary Angiography | 1 | 2016 | 232 | 0.420 |
Why?
|
| Incretins | 1 | 2014 | 15 | 0.420 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2014 | 20 | 0.420 |
Why?
|
| HIV Infections | 1 | 2023 | 952 | 0.410 |
Why?
|
| Hypertension, Portal | 3 | 2019 | 44 | 0.400 |
Why?
|
| Placebos | 3 | 2021 | 205 | 0.380 |
Why?
|
| Vitamin E | 3 | 2019 | 34 | 0.380 |
Why?
|
| Aged | 18 | 2025 | 20395 | 0.370 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2012 | 23 | 0.370 |
Why?
|
| Pregnancy Complications | 2 | 2013 | 350 | 0.360 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2025 | 24 | 0.360 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2021 | 18 | 0.360 |
Why?
|
| Metformin | 3 | 2019 | 126 | 0.350 |
Why?
|
| Mass Screening | 2 | 2017 | 706 | 0.350 |
Why?
|
| Cholesterol, HDL | 2 | 2025 | 173 | 0.350 |
Why?
|
| Dietary Fats | 2 | 2012 | 134 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 30 | 0.340 |
Why?
|
| Public Health | 3 | 2023 | 152 | 0.340 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 48 | 0.340 |
Why?
|
| Incidence | 7 | 2025 | 1697 | 0.320 |
Why?
|
| Gastroenterology | 2 | 2024 | 157 | 0.320 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2011 | 201 | 0.320 |
Why?
|
| Body Mass Index | 5 | 2020 | 806 | 0.320 |
Why?
|
| Pregnancy | 4 | 2017 | 3128 | 0.310 |
Why?
|
| Consensus | 5 | 2025 | 366 | 0.310 |
Why?
|
| Retrospective Studies | 10 | 2024 | 10128 | 0.310 |
Why?
|
| Logistic Models | 6 | 2021 | 1240 | 0.300 |
Why?
|
| Imidazoles | 2 | 2020 | 138 | 0.300 |
Why?
|
| Living Donors | 2 | 2002 | 347 | 0.290 |
Why?
|
| Sildenafil Citrate | 2 | 2019 | 24 | 0.280 |
Why?
|
| Leucine | 2 | 2019 | 56 | 0.280 |
Why?
|
| Europe | 4 | 2022 | 338 | 0.260 |
Why?
|
| Neoplasms | 1 | 2023 | 3168 | 0.260 |
Why?
|
| Prospective Studies | 11 | 2024 | 4546 | 0.260 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 35 | 0.260 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2006 | 36 | 0.260 |
Why?
|
| Ventricular Remodeling | 2 | 2020 | 99 | 0.260 |
Why?
|
| Liver Function Tests | 3 | 2021 | 91 | 0.250 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 28 | 0.240 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 37 | 0.240 |
Why?
|
| Body Weight | 3 | 2023 | 449 | 0.240 |
Why?
|
| Time Factors | 9 | 2024 | 5380 | 0.240 |
Why?
|
| Aspartate Aminotransferases | 2 | 2019 | 71 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 987 | 0.230 |
Why?
|
| Diet Therapy | 2 | 2016 | 19 | 0.230 |
Why?
|
| Glycerophospholipids | 1 | 2025 | 1 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 3450 | 0.230 |
Why?
|
| Chalcones | 1 | 2025 | 3 | 0.230 |
Why?
|
| Propionates | 1 | 2025 | 28 | 0.220 |
Why?
|
| Alcohol Abstinence | 3 | 2020 | 7 | 0.220 |
Why?
|
| Delivery, Obstetric | 2 | 2017 | 120 | 0.220 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 16 | 0.210 |
Why?
|
| Lipoproteins, VLDL | 2 | 2018 | 37 | 0.210 |
Why?
|
| Hypertriglyceridemia | 1 | 2025 | 71 | 0.210 |
Why?
|
| Body Composition | 1 | 2024 | 75 | 0.210 |
Why?
|
| Pyridazines | 1 | 2024 | 21 | 0.210 |
Why?
|
| Uracil | 1 | 2024 | 54 | 0.200 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 67 | 0.200 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.200 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 762 | 0.200 |
Why?
|
| Pathologists | 1 | 2023 | 40 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2024 | 256 | 0.190 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2003 | 43 | 0.190 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 3814 | 0.190 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2015 | 98 | 0.190 |
Why?
|
| Administration, Oral | 2 | 2021 | 655 | 0.190 |
Why?
|
| Critical Care | 1 | 2006 | 442 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 346 | 0.180 |
Why?
|
| Alcoholism | 1 | 2024 | 188 | 0.180 |
Why?
|
| Health Care Costs | 2 | 2022 | 248 | 0.180 |
Why?
|
| Signal Transduction | 2 | 2017 | 3497 | 0.180 |
Why?
|
| New Zealand | 1 | 2021 | 23 | 0.180 |
Why?
|
| France | 1 | 2021 | 52 | 0.180 |
Why?
|
| Germany | 1 | 2021 | 81 | 0.180 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2021 | 1 | 0.170 |
Why?
|
| Graft Survival | 4 | 2019 | 939 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 753 | 0.170 |
Why?
|
| Lipogenesis | 1 | 2021 | 25 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2019 | 1518 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 473 | 0.170 |
Why?
|
| Canada | 1 | 2021 | 194 | 0.170 |
Why?
|
| United Kingdom | 1 | 2021 | 189 | 0.170 |
Why?
|
| Triglycerides | 2 | 2018 | 231 | 0.170 |
Why?
|
| Lipids | 4 | 2021 | 277 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 239 | 0.160 |
Why?
|
| Nitriles | 1 | 2021 | 154 | 0.160 |
Why?
|
| Triazoles | 1 | 2021 | 110 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 99 | 0.160 |
Why?
|
| Isonicotinic Acids | 1 | 2020 | 1 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1160 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2465 | 0.160 |
Why?
|
| Azetidines | 1 | 2020 | 36 | 0.160 |
Why?
|
| Piperidines | 1 | 2021 | 163 | 0.160 |
Why?
|
| Needs Assessment | 1 | 2021 | 167 | 0.160 |
Why?
|
| Pectins | 1 | 2019 | 5 | 0.160 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2019 | 1 | 0.160 |
Why?
|
| Sulfoxides | 1 | 2019 | 6 | 0.150 |
Why?
|
| Benzothiazoles | 1 | 2019 | 17 | 0.150 |
Why?
|
| Galectin 3 | 1 | 2019 | 20 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2021 | 883 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2020 | 60 | 0.150 |
Why?
|
| Kidney | 1 | 2024 | 1093 | 0.150 |
Why?
|
| Isoxazoles | 1 | 2019 | 78 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 19 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 18 | 0.150 |
Why?
|
| Testosterone | 2 | 2019 | 258 | 0.150 |
Why?
|
| Education | 1 | 2019 | 58 | 0.150 |
Why?
|
| Weight Gain | 2 | 2017 | 127 | 0.150 |
Why?
|
| Benzamides | 1 | 2020 | 246 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 557 | 0.150 |
Why?
|
| Cholestenones | 1 | 2018 | 3 | 0.150 |
Why?
|
| Awareness | 1 | 2019 | 89 | 0.140 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 13 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2025 | 679 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 2787 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 449 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2019 | 212 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 638 | 0.140 |
Why?
|
| Pyridines | 1 | 2020 | 302 | 0.140 |
Why?
|
| Quality of Life | 3 | 2021 | 1776 | 0.130 |
Why?
|
| Everolimus | 1 | 2017 | 34 | 0.130 |
Why?
|
| Sex Factors | 2 | 2025 | 1102 | 0.130 |
Why?
|
| Models, Biological | 2 | 2019 | 1768 | 0.130 |
Why?
|
| Child | 4 | 2025 | 7273 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 140 | 0.130 |
Why?
|
| Early Diagnosis | 2 | 2019 | 135 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 56 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 246 | 0.130 |
Why?
|
| Obstetric Labor Complications | 1 | 2017 | 33 | 0.130 |
Why?
|
| Australia | 3 | 2021 | 120 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 3 | 2024 | 181 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2017 | 188 | 0.120 |
Why?
|
| Stroke | 2 | 2018 | 1073 | 0.120 |
Why?
|
| Animals | 8 | 2023 | 27968 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 214 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 517 | 0.120 |
Why?
|
| Tacrolimus | 1 | 2017 | 372 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 160 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2016 | 9 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1925 | 0.120 |
Why?
|
| Young Adult | 6 | 2020 | 6922 | 0.120 |
Why?
|
| Internationality | 1 | 2016 | 78 | 0.120 |
Why?
|
| Heart Failure | 2 | 2018 | 1376 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 649 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 267 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2016 | 94 | 0.110 |
Why?
|
| Graft Rejection | 2 | 2018 | 1123 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 448 | 0.110 |
Why?
|
| Adolescent | 7 | 2023 | 9550 | 0.110 |
Why?
|
| Injections, Subcutaneous | 2 | 2025 | 131 | 0.110 |
Why?
|
| Hepacivirus | 2 | 2019 | 135 | 0.110 |
Why?
|
| S-Adenosylmethionine | 1 | 2015 | 28 | 0.110 |
Why?
|
| Mice | 6 | 2023 | 12226 | 0.110 |
Why?
|
| Chicago | 2 | 2017 | 1452 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2015 | 93 | 0.110 |
Why?
|
| Leptin | 1 | 2015 | 100 | 0.110 |
Why?
|
| Antioxidants | 1 | 2016 | 231 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2015 | 91 | 0.110 |
Why?
|
| Liraglutide | 1 | 2014 | 8 | 0.110 |
Why?
|
| Recurrence | 4 | 2020 | 1188 | 0.110 |
Why?
|
| Age Factors | 2 | 2018 | 1898 | 0.110 |
Why?
|
| Inflammation | 2 | 2023 | 1048 | 0.110 |
Why?
|
| Insulin-Secreting Cells | 1 | 2018 | 441 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 102 | 0.100 |
Why?
|
| Cause of Death | 1 | 2015 | 271 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 415 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 916 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 874 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 258 | 0.100 |
Why?
|
| Heart Block | 1 | 2012 | 34 | 0.090 |
Why?
|
| Hospitalization | 2 | 2022 | 924 | 0.090 |
Why?
|
| Perhexiline | 1 | 2012 | 1 | 0.090 |
Why?
|
| Amiodarone | 1 | 2012 | 14 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 35 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1719 | 0.090 |
Why?
|
| Diet, Reducing | 1 | 2012 | 28 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2012 | 31 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2025 | 49 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 3890 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2012 | 39 | 0.090 |
Why?
|
| Cannabis | 1 | 2012 | 38 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2012 | 52 | 0.090 |
Why?
|
| Methotrexate | 1 | 2012 | 226 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 165 | 0.090 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 101 | 0.090 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2011 | 5 | 0.090 |
Why?
|
| Transcription Factor CHOP | 1 | 2011 | 16 | 0.090 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2011 | 18 | 0.090 |
Why?
|
| Choline | 1 | 2011 | 23 | 0.090 |
Why?
|
| Colic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Animal Feed | 1 | 2011 | 22 | 0.090 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 84 | 0.090 |
Why?
|
| Protein Phosphatase 1 | 1 | 2011 | 31 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2012 | 107 | 0.090 |
Why?
|
| Asia | 2 | 2021 | 108 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2025 | 827 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 217 | 0.080 |
Why?
|
| Headache | 1 | 2011 | 75 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 222 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 140 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2012 | 178 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 37 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 984 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 160 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2010 | 187 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 888 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 360 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 244 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2012 | 275 | 0.070 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 100 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 375 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2012 | 310 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2012 | 941 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2010 | 181 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 371 | 0.070 |
Why?
|
| Hepatocytes | 2 | 2022 | 129 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1260 | 0.070 |
Why?
|
| Viscera | 1 | 2008 | 19 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 31 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2010 | 364 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2019 | 3044 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 101 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2562 | 0.070 |
Why?
|
| Cytokines | 1 | 2011 | 862 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2018 | 866 | 0.060 |
Why?
|
| Organ Size | 1 | 2008 | 360 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2004 | 279 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 748 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2006 | 1 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2006 | 10 | 0.060 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2006 | 26 | 0.060 |
Why?
|
| Reference Values | 2 | 2019 | 603 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1703 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2705 | 0.060 |
Why?
|
| Fertility | 1 | 2006 | 119 | 0.060 |
Why?
|
| Brain Edema | 1 | 2006 | 54 | 0.060 |
Why?
|
| Intracranial Pressure | 1 | 2006 | 75 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 888 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2008 | 268 | 0.060 |
Why?
|
| Peroxisome Proliferators | 1 | 2004 | 2 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2004 | 8 | 0.050 |
Why?
|
| Skin | 1 | 2008 | 575 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2006 | 289 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2004 | 61 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2004 | 75 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3427 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 255 | 0.050 |
Why?
|
| Deficiency Diseases | 1 | 2004 | 12 | 0.050 |
Why?
|
| RNA | 1 | 2008 | 574 | 0.050 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2024 | 81 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 282 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 74 | 0.050 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2003 | 16 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 233 | 0.050 |
Why?
|
| Fasting | 1 | 2004 | 164 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 72 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 192 | 0.050 |
Why?
|
| Phenotype | 2 | 2024 | 2545 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 293 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2006 | 450 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 753 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 30 | 0.050 |
Why?
|
| Research | 1 | 2023 | 250 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 913 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 158 | 0.040 |
Why?
|
| Pruritus | 1 | 2021 | 30 | 0.040 |
Why?
|
| Abdomen | 1 | 2022 | 118 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 158 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 373 | 0.040 |
Why?
|
| Glucose | 1 | 2004 | 686 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 7 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 62 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2019 | 2 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 137 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1114 | 0.040 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 157 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 144 | 0.040 |
Why?
|
| Health Services | 1 | 2019 | 53 | 0.040 |
Why?
|
| Northwestern United States | 1 | 2018 | 7 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 400 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 161 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 63 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2019 | 90 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 820 | 0.040 |
Why?
|
| Insulin | 1 | 2004 | 1184 | 0.040 |
Why?
|
| Health Resources | 1 | 2019 | 78 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 457 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 315 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 55 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 833 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 199 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 494 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 393 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 134 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 69 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2017 | 24 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 188 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1519 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 63 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 774 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2017 | 92 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 91 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2017 | 55 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 120 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 301 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 218 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2021 | 432 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 748 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2018 | 455 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1945 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 627 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 245 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 134 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 371 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1004 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 451 | 0.030 |
Why?
|
| Calorimetry, Indirect | 1 | 2011 | 13 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2011 | 26 | 0.020 |
Why?
|
| Prealbumin | 1 | 2011 | 45 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2479 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 101 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2011 | 125 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2011 | 77 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 302 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 144 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 154 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 285 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2011 | 299 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 727 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 981 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1581 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 1866 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 824 | 0.020 |
Why?
|
| Catecholamine Plasma Membrane Transport Proteins | 1 | 2004 | 1 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 877 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 958 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2458 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1980 | 0.010 |
Why?
|